Shattering an old record, FDA quickly OKs pioneering, site-agnostic cancer drug larotrectinib from Loxo and Bayer

The FDA has hustled up a quick OK for larotrectinib, offering their stamp of approval for a site-agnostic cancer drug from Loxo Oncology and their partners at Bayer, a prime example of a new wave of oncology drugs hitting the field.